U.S. Intravenous Immunoglobulin Market Reaches USD 8.79 Bn in 2026, Driven by Rising Diagnosis of Immunodeficiency and Autoimmune Disorders

Growing Adoption of Immunoglobulin Therapies and Advances in Plasma Collection to Drive U.S. Intravenous Immunoglobulin Market to USD 10.03 Bn by 2033 at 8.2% CAGR – Coherent Market Insights

U.S. Intravenous Immunoglobulin Market, by Formulation (Liquid and Powder), by Application (Hypogammaglobulinemia, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Primary Immunodeficiency Diseases, Myasthenia Gravis, Multifocal Motor Neuropathy, Kawasaki Disease, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), is estimated to be valued at USD 8.79 Billion in 2026, and is expected to exhibit a CAGR of  8.2 %  during the forecast period (2026-2033).

Increasing number of product launches or approvals is expected to help in boosting growth of the U.S. intravenous immunoglobulin market. For instance, on January 19, 2016, Kedrion Biopharma, a company that develops plasma derived therapies announced that it had obtained exclusive rights to commercialize another immunoglobulin (IG) brand—BIVIGAM, a 10% liquid licensed by Germany-based Biotest Pharmaceuticals Corporation—in order to expand its growing presence in the U.S. Kedrion Biopharma Inc. is the U.S. subsidiary of Kedrion Biopharma, a global leader in the development and manufacturing of therapeutic plasma proteins.

Increase in number of acquisitions, partnerships, and collaborations between the market players is expected to propel the growth of the U.S. intravenous immunoglobulin market during the forecast period. For instance, on June 06, 2017, ADMA Biologics, Inc., a late-stage biopharmaceutical company that develops, manufactures, and commercializes specialty plasma-based biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases, announced that it had completed its acquisition of the assets of Biotest Pharmaceuticals Corporation's Therapy Business Unit (BTBU). As a result of this transaction, ADMA acquired two U.S. Food and Drugs Administration (FDA) approved products, Nabi-HB (Hepatitis B Immune Globulin, Human) and BIVIGAM (Immune Globulin Intravenous, Human).

Browse 35 Market Data Tables and 25 Figures spread through 210 Pages and in-depth TOC on the U.S. Intravenous Immunoglobulin Market, by Formulation (Liquid and Powder), by Application (Hypogammaglobulinemia, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Primary Immunodeficiency Diseases, Myasthenia Gravis, Multifocal Motor Neuropathy, Kawasaki Disease, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by

To know the latest trends and insights prevalent in the U.S. Intravenous Immunoglobulin Market, click the link below:

https://www.coherentmarketinsights.com/market-insight/us-intravenous-immunoglobulin-market-4829

Key Takeaways of the U.S. Intravenous Immunoglobulin Market

• The U.S. intravenous immunoglobulin market is expected to exhibit a CAGR of 8.2% over the forecast period (2026-2033). Increasing research and development activities, rising product launches and approvals, inorganic activities such as collaborations, agreements, acquisitions, and others are expected to drive growth of the S. intravenous immunoglobulin market. For instance, on February 09, 2021, Evolve Biologics Inc., a plasma-derived therapeutics company, announced the completion of its adult and pediatric Phase III clinical trial of PlasmaCap IG (Intravenous Immunoglobulin or IVIG), which was conducted at 12 study centers across the U.S. and Canada. PlasmaCap IG is an IVIG replacement therapy under investigation for adult and pediatric patients with primary immune deficiency disease (PIDD).
• Some of the major players operating in the U.S. intravenous immunoglobulin market include Biotest AG, Octapharma AG, Grifols S.A., Kedrion Biopharma, Inc., CSL Behring, McKesson Corporation, Takeda Pharmaceutical Company Limited, Bio Products Laboratory Ltd., Pfizer, Inc., and ADMA Biologics, Inc.

Key Development

• In May 2026, ADMA Biologics received U.S. FDA approval to expand ASCENIV’s label for treating primary humoral immunodeficiency in pediatric patients aged two years and older, compared with the previous minimum age of 12. The approval followed a supplemental Biologics License Application and completion of the required pediatric assessment. ASCENIV is a plasma-derived, polyclonal intravenous immunoglobulin designed to provide immune-compromised patients with naturally occurring antibodies against infections, supporting pediatric access. (Source: ADMA Biologics)
• In April 2026, GC Biopharma USA announced new research comparing aggregation profiles across commercially available 10% intravenous immunoglobulin products. Presented at the NHIA Annual Conference in Denver, the study assessed molecular size distribution and particle characteristics. Results showed ALYGLO’s purification process produced a high proportion of monomers and dimers with low polymer and fragment levels, supporting greater understanding of IVIG purity, stability, immunogenicity, infusion tolerability, manufacturing quality, and overall safety. (Source: GC Biopharma USA)
• In May 2026, Grifols reported strong U.S. uptake of Biotest’s next-generation IVIG, Yimmugo. The sugar-free, ready-to-use 10% IVIG is indicated for primary humoral immunodeficiency and contributed to 15.3% constant-currency growth in Grifols’ immunoglobulin franchise during the first quarter of 2026. (Source: Grifols)